Literature DB >> 25034089

A novel mutation (c.2735_2736delTC) in the androgen receptor gene in 46,XY females with complete androgen insensitivity syndrome in an Egyptian family.

Inas Mazen1, Hala Soliman, Mona El-Gammal, Ahmed Torky, Mona Mekkawy, Mohamed S Abdel-Hamid, Mona Essawi.   

Abstract

BACKGROUND: Androgen insensitivity syndrome (AIS) results from resistance of the target tissues to the effect of the androgenic hormones producing a phenotype with varying degrees of feminization ranging from male infertility to completely normal female external genitalia. Androgen receptor (AR) is a transcription factor that interacts with the androgenic steroids that act as ligands activating the AR, and via different cellular mechanisms, the activated AR binds to the DNA of target tissues to induce the desired biological changes. To date, more than 800 different mutations in the AR gene have been identified in patients with AIS and the majority of these mutations are localized in the ligand-binding domain.
METHODS: Here we describe an Egyptian family with 7 affected 46,XY females with complete androgen insensitivity.
RESULTS: Mutational analysis of the AR gene revealed a novel frameshift mutation in exon 8 of the gene c.2735_2736delTC.
CONCLUSION: This study extends the number of AR gene mutations identified so far. Further, it confirms that AR gene mutations are the most frequent cause of 46,XY disorder of sexual development, with higher frequency in the complete phenotype.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034089     DOI: 10.1159/000360292

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  1 in total

1.  A missense mutation in the androgen receptor gene causing androgen insensitivity syndrome in a Chinese family.

Authors:  Lin Li; Wen-Miao Liu; Mei-Xin Liu; Shu-Qi Zheng; Ji-Xia Zhang; Feng-Yuan Che; Shi-Guo Liu
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.